| Code | 9426D | ||||||||||
| MA number | 44/0004/22-S | ||||||||||
| Product Form: | cif fol 1x1,5 ml/60 mg konc.+1x4,5 ml solv.(liek.inj.skl.) | ||||||||||
| MA Status: | R - Valid Marketing Authorisation | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | MSN LABS EUROPE Limited, Malta | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Container: | glass vial | ||||||||||
| Route of admin.: | Intravenous use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 18.02.2022 |
| Validity: | 18.02.2027 |
| SPC: |
SPC_Cabazitaxel MSN_09.2023.pdf
|
| PIL: |
PIL_Cabazitaxel MSN_09.2023.pdf
|
| Safety feature | Yes |
| Data update: | 09.03.2022 |
